AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)
AbCellera Biologics' (ABCL) quarterly Long-Term Debt Issuances came in at $5.9 million in Q4 2024, up 17.28% YoY from $5.0 million in Q1 2024, and up 90.17% on a QoQ basis from $3.1 million in Q3 2024.
AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024) Analysis & Trends
AbCellera Biologics (ABCL) has 5 years of Long-Term Debt Issuances data on file, last reported at $5.9 million in Q4 2024.
- Quarterly Long-Term Debt Issuances rose 17.28% year-over-year to $5.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $13.5 million (up 16.46% YoY) and the FY2025 annual result came in at $29.7 million, up 120.26% from the prior year.
- Long-Term Debt Issuances grew to $5.9 million in Q4 2024, from $3.1 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $16.2 million in Q1 2020 to a low of -$662000.0 in Q2 2020.
- A 5-year average of $2.9 million and a median of $1.9 million in 2021 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2021 — Long-Term Debt Issuances jumped 12728.57% — and 2022, when it sank 80.97%.
- Tracing ABCL's Long-Term Debt Issuances over 5 years: stood at $974000.0 in 2020, then surged by 88.3% to $1.8 million in 2021, then slumped by 80.97% to $349000.0 in 2022, then surged by 1341.26% to $5.0 million in 2023, then increased by 17.28% to $5.9 million in 2024.
- The last three Long-Term Debt Issuances figures came in at $5.9 million (Q4 2024), $3.1 million (Q3 2024), and $2.4 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.90 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 2.37 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Dec 31, 2022 | 349,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1.94 Mn |
| Mar 31, 2022 | 1.94 Mn |